• Something wrong with this record ?

Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival

A. Martini, C. Lonati, A. Necchi, MD. Galsky, G. Ploussard, G. Fallara, A. Pellegrino, C. Simeone, N. Suardi, S. Zamboni, W. Krajewski, G. Simone, A. Briganti, F. Montorsi, A. Mattei, SF. Shariat, M. Moschini, European Association of Urology -...

. 2022 ; 20 (4) : 389.e1-389.e7. [pub] 20220310

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22024988

INTRODUCTION: The only phase III trial that evaluated the role of adjuvant chemotherapy following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) was terminated early. Thus, eventual overall survival (OS) surrogacy, as per Prentice, cannot be assessed in this setting. We aimed to identify an intermediate clinical endpoint (ICE) that could serve as an OS surrogate after RNU for UTUC. PATIENTS AND METHODS: We retrospectively analyzed 823 high-grade UTUC patients treated with RNU at 8 tertiary referral centers. We explored the role of any recurrence (aR), defined as recurrence in the urinary tract or in the resection bed as well the presence of distant metastasis (DM), defined as metastatic disease outside the urinary tract and regional lymph nodes, on OS through a time-varying Cox regression analyses fitted at the landmark points of 1, 2, 3, and 4 years from RNU. Models' discrimination was assessed using Harrell's c index, after internal validation. RESULTS: Median follow-up for survivors was 5.6 years (interquartile range: 2.0-8.8). Overall, 391 and 212 patients experienced aR and DM, respectively. In a time-varying model, aR and DM were predictors of OS: hazard ratio [HR]:1.20, 95% confidence interval [CI]: 1.13-1.28 (P < .001) and HR:1.26, 95% CI: 1.18-1.34 (P < .001), respectively. Progression to DM within 3 years from RNU was the most informative ICE for predicting OS (c index: 0.81; HR: 4.40; 95%CI: 2.45-7.92; P < .001), compared to DM within 1, 2, and 4 years (c indexes: 0.74, 0.76, and 0.78, respectively). Progression to DM within 3 years from RNU was further found superior for predicting OS compared to aR at any landmark points. CONCLUSIONS: Progression to DM within 3 years represents a potential OS surrogate for surgically-treated UTUC. This information could help in patient counseling, future study design and expedite results release of ongoing randomized controlled trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024988
003      
CZ-PrNML
005      
20221031100808.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clgc.2022.03.007 $2 doi
035    __
$a (PubMed)35383003
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Martini, Alberto $u Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Urology, La Croix du Sud Hospital, Institut Universitaire du Cancer Toulouse-Oncopole, Toulose, France. Electronic address: a.martini.md@gmail.com
245    10
$a Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival / $c A. Martini, C. Lonati, A. Necchi, MD. Galsky, G. Ploussard, G. Fallara, A. Pellegrino, C. Simeone, N. Suardi, S. Zamboni, W. Krajewski, G. Simone, A. Briganti, F. Montorsi, A. Mattei, SF. Shariat, M. Moschini, European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.
520    9_
$a INTRODUCTION: The only phase III trial that evaluated the role of adjuvant chemotherapy following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) was terminated early. Thus, eventual overall survival (OS) surrogacy, as per Prentice, cannot be assessed in this setting. We aimed to identify an intermediate clinical endpoint (ICE) that could serve as an OS surrogate after RNU for UTUC. PATIENTS AND METHODS: We retrospectively analyzed 823 high-grade UTUC patients treated with RNU at 8 tertiary referral centers. We explored the role of any recurrence (aR), defined as recurrence in the urinary tract or in the resection bed as well the presence of distant metastasis (DM), defined as metastatic disease outside the urinary tract and regional lymph nodes, on OS through a time-varying Cox regression analyses fitted at the landmark points of 1, 2, 3, and 4 years from RNU. Models' discrimination was assessed using Harrell's c index, after internal validation. RESULTS: Median follow-up for survivors was 5.6 years (interquartile range: 2.0-8.8). Overall, 391 and 212 patients experienced aR and DM, respectively. In a time-varying model, aR and DM were predictors of OS: hazard ratio [HR]:1.20, 95% confidence interval [CI]: 1.13-1.28 (P < .001) and HR:1.26, 95% CI: 1.18-1.34 (P < .001), respectively. Progression to DM within 3 years from RNU was the most informative ICE for predicting OS (c index: 0.81; HR: 4.40; 95%CI: 2.45-7.92; P < .001), compared to DM within 1, 2, and 4 years (c indexes: 0.74, 0.76, and 0.78, respectively). Progression to DM within 3 years from RNU was further found superior for predicting OS compared to aR at any landmark points. CONCLUSIONS: Progression to DM within 3 years represents a potential OS surrogate for surgically-treated UTUC. This information could help in patient counseling, future study design and expedite results release of ongoing randomized controlled trials.
650    12
$a karcinom z přechodných buněk $x farmakoterapie $7 D002295
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a lidé $7 D006801
650    _2
$a nefroureterektomie $7 D000074682
650    _2
$a retrospektivní studie $7 D012189
650    12
$a nádory močového měchýře $x chirurgie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lonati, Chiara $u Department of Urology, Spedali Civili of Brescia, Brescia, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Necchi, Andrea $u Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Galsky, Matthew D $u Department of Medicine, Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
700    1_
$a Ploussard, Guillaume $u Department of Urology, La Croix du Sud Hospital, Institut Universitaire du Cancer Toulouse-Oncopole, Toulose, France
700    1_
$a Fallara, Giuseppe $u Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Pellegrino, Antony $u Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Simeone, Claudio $u Department of Urology, Spedali Civili of Brescia, Brescia, Italy
700    1_
$a Suardi, Nazareno $u Department of Urology, Spedali Civili of Brescia, Brescia, Italy
700    1_
$a Zamboni, Stefania $u Department of Urology, Spedali Civili of Brescia, Brescia, Italy
700    1_
$a Krajewski, Wojciech $u Department of Urology and Oncological Urology, Wroclaw Medical University, Wrocław, Poland
700    1_
$a Simone, Giuseppe $u Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy
700    1_
$a Briganti, Alberto $u Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Montorsi, Francesco $u Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Mattei, Agostino $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Moschini, Marco $u Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland
710    2_
$a European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.
773    0_
$w MED00188741 $t Clinical genitourinary cancer $x 1938-0682 $g Roč. 20, č. 4 (2022), s. 389.e1-389.e7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35383003 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100805 $b ABA008
999    __
$a ok $b bmc $g 1854603 $s 1176278
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 20 $c 4 $d 389.e1-389.e7 $e 20220310 $i 1938-0682 $m Clinical genitourinary cancer $n Clin Genitourin Cancer $x MED00188741
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options